Radio-opaque contrast agents for liver cancer targeting
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).
Protocol paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11462695/
Trial information: https://clinicaltrials.gov/study/NCT05169177